How We Can Support the Drug Development Pipeline

KRAS - Gene Mutation Analysis

 In different cancer types, in particular those of colorectum and lung, certain subsets of patients have been shown to benefit from anti-EGFR therapies; however a significant proportion show no benefit from these agents. The KRAS gene encodes a protein that plays a key role in transmitting the original signal from EGFR downstream to activate important cell functions, in particular proliferation and survival. Acquired mutations of this gene commonly occur in pancreatic, colorectal and lung tumours. These mutations are activating, leading to uncontrolled signalling. They occur primarily in one small region of the gene and make tumours resistant to anti-EGFR therapies. Patients with such mutations in their tumours are therefore considered unlikely to benefit from anti-EGFR therapies. Current guidelines in the US and Europe suggest that all patients being considered for such therapies should be tested for KRAS mutations.

Source BioScience is a UK preferred supplier of KRAS mutation testing, providing histopathology review of the tumour sample and macrodissection. KRAS mutation testing is offered based on two alternative CE-marked technologies, both suitable for archival FFPE tissue samples:

• The DxS Therascreen™ KRAS Mutation Test uses real-time PCR to detect the 7 most common activating mutations found in the KRAS gene
• Pyrosequencing using the Qiagen/Biotage PyroMark™ KRAS Test provides an alternative technique for evaluating the same 7 mutations

These mutations, all located in exon 2, are associated with resistance to the anti-EGFR monoclonal antibody therapeutics cetuximab (Erbitux™) and panitumumab (Vectibix™), and the small molecule inhibitors of EGFR gefitinib (Iressa™) and erlotinib (Tarceva™). The results of mutation tests are reported as positive or negative for the presence of a particular mutation, along with additional information about relative frequencies of particular mutations in colorectal and lung tumours.

References:

• National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer. Published online November 2008. more info
• van Krieken et al. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417

For further information please contact us at: Pharma